FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 10/2024”.
The Monitor is a month-to-month printed overview of enterprise capital tendencies within the US Healthcare & Life Sciences sector.
As of the tip of October 2024 we recognized the next present VC tendencies in the US:
- Complete Healthcare & Life Sciences funding reached EUR 7,381m
- Biotech/Pharma acquired 60% of the entire funding quantity (EUR 4,442m) with oncology being the main indication (44%)
- In October, Nelly (Germany) secured the very best transaction quantity with EUR 100m, adopted by Purespring Therapeutics (United Kingdom) with EUR 95m and AgomAb (Belgium) with EUR 89m
- Common Atlantic (United States) is probably the most lively investor (by deal quantity in 2024), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To entry the total report, please click on right here.
